CGM Use in Adults With Type 2 Diabetes on Basal Insulin

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 469 participants.

Also called NCT05944432

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 469 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05944432
Main results
  • Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial The lancet. Diabetes & endocrinology, 2026-06 DOI, PubMed 42035781

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05944432. Randomized; no masking; primary purpose treatment. Start 2023-07-26 (actual); primary completion 2026-02-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
Condition
Diabetes Mellitus, Type 2
Intervention (Device)
FreeStyle Libre 3 Continuous Glucose Monitoring System.
Intervention (Device)
Self monitoring of blood glucose
Lead sponsor
Abbott Diabetes Care (class: industry)

Record details

Record id
cardio:ct-nct05944432
Content hash
295c76586de3c1882938e3f59253c2c92d0a18678c736ab6edf36e12b8852f3b